LMR Partners LLP Purchases New Shares in Alto Neuroscience, Inc. (NYSE:ANRO)

LMR Partners LLP purchased a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 51,700 shares of the company’s stock, valued at approximately $219,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Integral Health Asset Management LLC acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at about $1,269,000. Graham Capital Management L.P. acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at about $204,000. Deutsche Bank AG grew its stake in shares of Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after acquiring an additional 3,629 shares in the last quarter. Corton Capital Inc. acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at about $142,000. Finally, Cantor Fitzgerald L. P. acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at about $1,575,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ANRO shares. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. HC Wainwright started coverage on shares of Alto Neuroscience in a research note on Monday, April 7th. They set a “buy” rating and a $10.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.40.

Alto Neuroscience Trading Down 6.3%

Shares of Alto Neuroscience stock opened at $2.22 on Thursday. The company has a market capitalization of $60.10 million, a price-to-earnings ratio of -0.87 and a beta of 1.87. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a 12-month low of $1.60 and a 12-month high of $17.55. The firm’s 50-day moving average price is $2.41 and its two-hundred day moving average price is $3.46.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.06. On average, analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.